8 results on '"Torkko, Kathleen"'
Search Results
2. Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.
- Author
-
Schenk, Jeannette M., Till, Cathee A., Tangen, Catherine M., Goodman, Phyllis J., Xiaoling Song, Torkko, Kathleen C., Kristal, Alan R., Peters, Ulrike, and Neuhouser, Marian L.
- Abstract
The article focuses on study on association of Serum 25-Hydroxyvitamin D concentrations and risk of prostate cancer based on the Prostate Cancer Prevention Trial. It mentions the analysis of Baseline serum for 25-hydroxyvitamin D [25(OH)D] and determination of presence or absence of cancer by prostate biopsy. It adds that Vitamin D may have effect on different stages of prostate cancers. It also adds results for placebo and finasteride arms.
- Published
- 2014
- Full Text
- View/download PDF
3. MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1 .
- Author
-
Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, and Cramer SD
- Subjects
- Androgens pharmacology, Benzamides pharmacology, Cell Cycle drug effects, Cell Cycle genetics, Cell Line, Tumor, Cell Proliferation drug effects, Cell Proliferation genetics, DNA Helicases metabolism, DNA-Binding Proteins metabolism, Drug Resistance, Neoplasm drug effects, Drug Resistance, Neoplasm genetics, Gene Expression Regulation, Neoplastic, Humans, Logistic Models, MAP Kinase Kinase Kinases metabolism, Male, Neoplasm Recurrence, Local, Nitriles pharmacology, Phenylthiohydantoin pharmacology, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Receptors, Androgen metabolism, Risk Factors, DNA Helicases genetics, DNA-Binding Proteins genetics, MAP Kinase Kinase Kinases genetics, Prostatic Neoplasms genetics, RNA Interference, Receptors, Androgen genetics, Signal Transduction genetics
- Abstract
Prostate cancer genomic subtypes that stratify aggressive disease and inform treatment decisions at the primary stage are currently limited. Previously, we functionally validated an aggressive subtype present in 15% of prostate cancer characterized by dual deletion of MAP3K7 and CHD1 . Recent studies in the field have focused on deletion of CHD1 and its role in androgen receptor (AR) chromatin distribution and resistance to AR-targeted therapy; however, CHD1 is rarely lost without codeletion of MAP3K7 . Here, we show that in the clinically relevant context of co-loss of MAP3K7 and CHD1 there are significant, collective changes to aspects of AR signaling. Although CHD1 loss mainly impacts the expansion of the AR cistrome, loss of MAP3K7 drives increased AR target gene expression. Prostate cancer cell line models engineered to cosuppress MAP3K7 and CHD1 also demonstrated increased AR-v7 expression and resistance to the AR-targeting drug enzalutamide. Furthermore, we determined that low protein expression of both genes is significantly associated with biochemical recurrence (BCR) in a clinical cohort of radical prostatectomy specimens. Low MAP3K7 expression, however, was the strongest independent predictor for risk of BCR over all other tested clinicopathologic factors including CHD1 expression. Collectively, these findings illustrate the importance of MAP3K7 loss in a molecular subtype of prostate cancer that poses challenges to conventional therapeutic approaches. IMPLICATIONS: These findings strongly implicate MAP3K7 loss as a biomarker for aggressive prostate cancer with significant risk for recurrence that poses challenges for conventional androgen receptor-targeted therapies., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
4. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1 -Mutant Breast Cancer.
- Author
-
Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, and Richer JK
- Subjects
- Fulvestrant pharmacology, Gene Expression, Humans, Mutation, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Estrogen Receptor alpha genetics
- Abstract
Mutations in ESR1 that confer constitutive estrogen receptor alpha (ER) activity in the absence of ligand are acquired by ≥40% of metastatic breast cancers (MBC) resistant to adjuvant aromatase inhibitor (AI) therapy. To identify targetable vulnerabilities in MBC, we examined steroid hormone receptors and tumor-infiltrating immune cells in metastatic lesions with or without ER mutations. ER and progesterone receptor (PR) were significantly lower in metastases with wild-type (WT) ER compared with those with mutant ER, suggesting that metastases that evade AI therapy by mechanism(s) other than acquiring ER mutations lose dependency on ER and PR. Metastases with mutant ER had significantly higher T regulatory and Th cells, total macrophages, and programmed death ligand-1 (PD-L1)-positive immune-suppressive macrophages than those with WT ER. Breast cancer cells with CRISPR-Cas9-edited ER (D538G, Y537S, or WT) and patient-derived xenografts harboring mutant or WT ER revealed genes and proteins elevated in mutant ER cells, including androgen receptor (AR), chitinase-3-like protein 1 (CHI3L1), and IFN-stimulated genes (ISG). Targeting these proteins blunted the selective advantage of ER-mutant tumor cells to survive estrogen deprivation, anchorage independence, and invasion. Thus, patients with mutant ER MBC might respond to standard-of-care fulvestrant or other selective ER degraders when combined with AR or CHI3L1 inhibition, perhaps with the addition of immunotherapy. SIGNIFICANCE: Targetable alterations in MBC, including AR, CHI3L1, and ISG, arise following estrogen-deprivation, and ER-mutant metastases may respond to immunotherapies due to elevated PD-L1
+ macrophages. See related article by Arnesen et al., p. 539 ., (©2020 American Association for Cancer Research.)- Published
- 2021
- Full Text
- View/download PDF
5. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.
- Author
-
Torkko K, Till C, Tangen CM, Goodman PJ, Song X, Schenk JM, Lucia MS, Peters U, van Bokhoven A, Thompson IM, and Neuhouser ML
- Subjects
- 25-Hydroxyvitamin D3 1-alpha-Hydroxylase genetics, 5-alpha Reductase Inhibitors therapeutic use, Adenocarcinoma epidemiology, Adenocarcinoma prevention & control, Black or African American genetics, Aged, Aged, 80 and over, Case-Control Studies, Finasteride therapeutic use, Genetic Predisposition to Disease, Genotype, Humans, Male, Metabolic Networks and Pathways genetics, Middle Aged, Prostatic Neoplasms epidemiology, Prostatic Neoplasms prevention & control, Randomized Controlled Trials as Topic statistics & numerical data, Risk, Vitamin D analogs & derivatives, Vitamin D blood, White People genetics, Adenocarcinoma genetics, Polymorphism, Single Nucleotide, Prostatic Neoplasms genetics, Vitamin D metabolism
- Abstract
Vitamin D may influence prostate cancer risk, but evidence is inconsistent. We conducted a nested case-control study in the Prostate Cancer Prevention Trial (PCPT). Cases ( n = 1,128) and controls ( n = 1,205) were frequency matched on age, first-degree relative with prostate cancer, and PCPT treatment arm (finasteride/placebo); African-Americans were oversampled and case/control status was biopsy confirmed. We selected 21 SNPs in vitamin D-related genes (VDR, GC, C10orf88, CYP2R1, CYP24A1, CYP27B1, DHCR7 , and NADSYN1 ) to test genotype and genotype-treatment interactions in relation to prostate cancer. We also tested mean serum 25(OH)D differences by minor allele distributions and tested for serum 25(OH)D-genotype interactions in relation to prostate cancer risk. Log-additive genetic models (Bonferroni-corrected within genes) adjusted for age, body mass index, PSA, and family history of prostate cancer revealed a significant interaction between treatment arm and GC /rs222016 (finasteride OR = 1.37, placebo OR = 0.85; P
interaction < 0.05), GC /rs222014 (finasteride OR = 1.36, placebo OR = 0.85; Pinteraction < 0.05), and CYP27B1 /rs703842 (finasteride OR = 0.76, placebo OR = 1.10; Pinteraction < 0.05) among Caucasians, and C10orf88 /rs6599638 (finasteride OR = 4.68, placebo OR = 1.39; Pinteraction < 0.05) among African-Americans. VDR/ rs1544410 and CYP27B1 /rs703842 had significant treatment interactions for high-grade disease among Caucasians (finasteride OR = 0.81, placebo OR = 1.40; Pinteraction < 0.05 and finasteride OR = 0.70, placebo OR = 1.28; Pinteraction < 0.05, respectively). Vitamin D-related SNPs influenced serum 25(OH)D, but gene-serum 25(OH)D effect modification for prostate cancer was marginally observed only for CYP24A1 /rs2248359. In conclusion, evidence that vitamin D-related genes or gene-serum 25(OH)D associations influence prostate cancer risk is modest. We found some evidence for gene-finasteride interaction effects for prostate cancer in Caucasians and African-Americans. Results suggest only minimal associations of vitamin D with total or high-grade prostate cancer., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF
6. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
- Author
-
Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, and Richer JK
- Subjects
- Breast Neoplasms enzymology, Breast Neoplasms immunology, Breast Neoplasms pathology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Female, Humans, Kynurenine pharmacology, Lymphocytes, Tumor-Infiltrating enzymology, Lymphocytes, Tumor-Infiltrating immunology, Tryptophan Oxygenase immunology, Breast Neoplasms blood, CD8-Positive T-Lymphocytes enzymology, Tryptophan blood, Tryptophan Oxygenase blood
- Abstract
Tryptophan catabolism is an attractive target for reducing tumor progression and improving antitumor immunity in multiple cancers. Tumor infiltration by CD8 T cells correlates with improved prognosis in triple-negative breast cancer (TNBC) and a significant effort is underway to improve CD8 T-cell antitumor activity. In this study, primary human immune cells were isolated from the peripheral blood of patients and used to demonstrate that the tryptophan catabolite kynurenine induces CD8 T-cell death. Furthermore, it is demonstrated that anchorage-independent TNBC utilizes the tryptophan-catabolizing enzyme tryptophan 2,3-dioxygenase (TDO) to inhibit CD8 T-cell viability. Publicly available data revealed that high TDO2 , the gene encoding TDO, correlates with poor breast cancer clinical outcomes, including overall survival and distant metastasis-free survival, while expression of the gene encoding the more commonly studied tryptophan-catabolizing enzyme, IDO1 did not. Metabolomic analysis, using quantitative mass spectrometry, of tryptophan and its catabolites, including kynurenine, in the plasma from presurgical breast cancer patients ( n = 77) and 40 cancer-free donors ( n = 40) indicated a strong correlation between substrate and catabolite in both groups. Interestingly, both tryptophan and kynurenine were lower in the plasma from patients with breast cancer compared with controls, particularly in women with estrogen receptor (ER)-negative and stage III and IV breast cancer. IMPLICATIONS: This study underscores the importance of tryptophan catabolism, particularly in aggressive disease, and suggests that future pharmacologic efforts should focus on developing drugs that target both TDO and IDO1., (©2018 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
7. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
- Author
-
D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, and Richer JK
- Subjects
- Anilides pharmacology, Benzamides, Binding Sites, Breast Neoplasms metabolism, Cell Line, Tumor, Cell Nucleus metabolism, Cell Proliferation drug effects, Cyclohexanes pharmacology, Disease Progression, Estradiol, Female, Humans, MCF-7 Cells, Nitriles, Phenylthiohydantoin administration & dosage, Phenylthiohydantoin pharmacology, Receptors, Estrogen metabolism, Tamoxifen pharmacology, Breast Neoplasms genetics, Chromatin metabolism, Drug Resistance, Neoplasm drug effects, Phenylthiohydantoin analogs & derivatives, Receptors, Androgen metabolism, Receptors, Estrogen genetics, Tamoxifen administration & dosage
- Abstract
Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha-positive (ER
+ ) breast tumors, but its role in tumor growth and progression remains controversial. Use of two anti-androgens that inhibit AR nuclear localization, enzalutamide and MJC13, revealed that AR is required for maximum ER genomic binding. Here, a novel global examination of AR chromatin binding found that estradiol induced AR binding at unique sites compared with dihydrotestosterone (DHT). Estradiol-induced AR-binding sites were enriched for estrogen response elements and had significant overlap with ER-binding sites. Furthermore, AR inhibition reduced baseline and estradiol-mediated proliferation in multiple ER+ /AR+ breast cancer cell lines, and synergized with tamoxifen and fulvestrant. In vivo, enzalutamide significantly reduced viability of tamoxifen-resistant MCF7 xenograft tumors and an ER+ /AR+ patient-derived model. Enzalutamide also reduced metastatic burden following cardiac injection. Finally, in a comparison of ER+ /AR+ primary tumors versus patient-matched local recurrences or distant metastases, AR expression was often maintained even when ER was reduced or absent. These data provide preclinical evidence that anti-androgens that inhibit AR nuclear localization affect both AR and ER, and are effective in combination with current breast cancer therapies. In addition, single-agent efficacy may be possible in tumors resistant to traditional endocrine therapy, as clinical specimens of recurrent disease demonstrate AR expression in tumors with absent or refractory ER., Implications: This study suggests that AR plays a previously unrecognized role in supporting E2-mediated ER activity in ER+ /AR+ breast cancer cells, and that enzalutamide may be an effective therapeutic in ER+ /AR+ breast cancers. Mol Cancer Res; 14(11); 1054-67. ©2016 AACR., Competing Interests: Vernon T. Phan is a fulltime employee of Medivation, Inc., (©2016 American Association for Cancer Research.)- Published
- 2016
- Full Text
- View/download PDF
8. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
- Author
-
Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, and Jones FE
- Subjects
- Breast Neoplasms pathology, Cell Line, Tumor, Humans, Immunohistochemistry, Mitochondria metabolism, Proto-Oncogene Proteins metabolism, Antineoplastic Agents, Hormonal pharmacology, Apoptosis drug effects, Receptors, Estrogen agonists, Tamoxifen pharmacology, Transcription Factors metabolism
- Abstract
Greater than 40% of breast cancer patients treated with tamoxifen exhibit de novo or acquired tumor resistance. Recent clinical evidence indicates that loss of expression of HER4 is an independent marker for tamoxifen resistance. In direct corroboration with clinical observations, suppression of HER4 expression in the tamoxifen-sensitive MCF-7 and T47D breast tumor cell lines resulted in resistance to tamoxifen-induced apoptosis. Furthermore, HER4 expression was lost in three independent MCF-7 models of acquired tamoxifen resistance. The HER4 intracellular domain (4ICD) is an independently signaling nuclear protein that functions as a potent ERalpha coactivator. In addition, mitochondrial 4ICD functions as a proapoptotic BH3-only protein. Tamoxifen disrupts an estrogen-driven interaction between ERalpha and 4ICD while promoting mitochondrial accumulation of the 4ICD BH3-only protein. BCL-2 inhibition of tamoxifen-induced apoptosis and tamoxifen activation of BAK, independent of BAX, further supports a role for 4ICD during tamoxifen-induced apoptosis. Finally, reintroduction of HER4, but not HER4 with a mutated BH3 domain, restores tamoxifen sensitivity to tamoxifen-resistant TamR cells in a xenograft model. Clinically, breast cancer patients with tumor expression of nuclear 4ICD responded to tamoxifen therapy with no clinical failures reported after 14 years of follow-up, whereas 20% of patients lacking nuclear 4ICD expression succumbed to their disease within 10 years of diagnosis. Our identification of the HER4/4ICD BH3-only protein as a critical mediator of tamoxifen action provides a clinically important role for 4ICD in human cancer and reveals a potential tumor marker to predict patient response to tamoxifen therapy.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.